KRAS and cancer: The recent finding that inhibitors of the protein-protein interactions of the phosphopeptide-binding Polo-box domains of Polo-like kinases can be used to target KRAS mutant cancers (Narvaez et al., 2017) speaks to the future therapeutic potential for such a strategy.